Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225287 | 1.00 | DPP4 (0.47) | DPP4DPP7TAAR1IDO1CYP3A4 | |
| SCHEMBL7955916 | 1.00 | DPP4 (0.47) | DPP4DPP7TAAR1IDO1CYP3A4 | |
| Carbamic Acid SCHEMBL28108559 | 0.91 | DPP4 (0.48) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| SCHEMBL5231615 | 0.85 | DPP4 (0.49) | DPP4DPP7TAAR1IDO1 | |
| SCHEMBL5231613 | 0.85 | DPP4 (0.49) | DPP4DPP7TAAR1IDO1 | |
| SCHEMBL7216586 | 0.82 | TAAR1 (0.54) | DPP4DPP7TAAR1IDO1CYP3A4 | |
| SCHEMBL4674867 | 0.82 | TAAR1 (0.54) | DPP4DPP7TAAR1IDO1CYP3A4 | |
| SCHEMBL7214170 | 0.80 | TAAR1 (0.47) | DPP4DPP7TAAR1IDO1CYP3A4 | |
| SCHEMBL27999583 | 0.80 | TAAR1 (0.52) | DPP4DPP7TAAR1IDO1CYP3A4 | |
| SCHEMBL978947 | 0.79 | DPP4 (0.57) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013056015-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| EP-1491537-B1 | HYDROXYMORPHOLINONE DERIVATIVE AND MEDICINAL USE THEREOF | SENJU PHARMA CO (JP) | 2010-07-07 | — | — | EP | disclosed |
| CN-100422161-C | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMA CO (JP) | 2008-10-01 | — | — | CN | disclosed |
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| EP-1092435-B1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO KK (JP) | 2007-04-04 | — | — | EP | disclosed |
| CN-1656084-A | Hydroxymorpholone derivative and medical application thereof | SENJU PHARMA CO (JP) | 2005-08-17 | — | — | CN | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6489331-B1 | A CONDENSED PURINE DERIVATIVE AS AN ACTIVE INGREDIENT AS AN ENHANCER OF INSULIN SECRETION AND A MEDICAMENT FOR THE TREATMENT OF DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| EP-1092435-A1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | DPP4 737/4885DPP7 538/4885TAAR1 1953/4885 |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | MTOR, PDPK1, PIK3CA | DPP4 2388/4885DPP7 1344/4885TAAR1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.